Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Keep scrolling down on the site and you will find another link.
Last Nighs Fights- Silva vs Henderson- Link attached
http://mmafightvideos.blogspot.com/
--The YouTube of MMA-- MMA Tube (web site) Link attached:
http://www.mma-tube.com/
Link Down/Kimbo vs Abbott. Will repost later......
Kimbo Slice vs Tank Abbott Fight Video:
http://mmafightvideos.blogspot.com/
ETFC Moving............
2-15-2008: Yahoo-Real Estate-Las Vegas- info attached
The property goes up for public auction tomorrow 2-15-08. Go to yahoo.com-Real Estate-Las Vegas-Foreclosures and see #15 for info.
This property is a Notice of Foreclosure Sale. A notice was filed at the recorder's office by the lender's attorney signifying a public auction. This 12406 square foot property has 0 bedroom(s) and 0 bath(s). The estimated bid amount is $5000000. This property will be auctioned at public sale on Feb 15, 2008. To access more extensive information on this property click the 'more property detail' link below. You will need to register for full access. Information listed with each property including estimated loan balance is derived from sources deemed accurate but we do not guarantee the accuracy of such information. Please consult all relevant title documents prior to purchase...
Register with RealtyTrac for more Property Detail
Year Built:
School District:
MLS Number:
Listed Date: February 01, 2008
------WEC 32 : Link Attached----------------
http://mmafightvideos.blogspot.com/
Kimbo Slice vs Sean Gannon-Kimbos only loss.Link attached
http://www.dailymotion.com/relevance/search/kimbo%2Bslice%2Bvs%2Bsean%2Bgannon/video/x2ymaq_kimbo-slice-vs-sean-gannon
100,000 Block went by- AIRN..............
---------------UFC 81 All Fights---------------s
http://mmafightvideos.blogspot.com/
G60- Thanks- ETFC + .43..........s
Nice DEIX News: Best Buy to Begin Offering Directed's Polk Audio Brand in June 2008
BALTIMORE, Jan. 31 /PRNewswire-FirstCall/ -- Polk Audio, a Directed Electronics brand (Nasdaq: DEIX), today announced that a wide selection of the company's home audio entertainment products will soon be available at more than 900 Best Buy locations throughout the U.S.
(Logo: http://www.newscom.com/cgi-bin/prnh/20020424/DIRECTLOGO)
Jim Minarik, President and CEO of Directed Electronics, commented, 'We have been very pleased with the performance of Polk Audio since our acquisition of the company in 2006. This opportunity with Best Buy greatly expands the market presence of Polk's marquee brand through one of the most exciting retailers in the history of home entertainment. This expansion also complements our existing product offerings at Best Buy and strengthens our leading position in the home audio market.'
Polk's upcoming TSi Series high performance/high value loudspeakers, as well as PSW powered subwoofers, select RM Series models, and the award-winning new SurroundBar(R) 360 DVD Theater two-piece system will arrive this coming June at Best Buy stores across the United States and online at http://www.bestbuy.com. Additionally, the Polk I-Sonic(R) Entertainment System 2, with iTunes(R) Tagging for HD Radio(R), will be featured in select Best Buy locations.
'From the company's beginning in 1972, Polk Audio has been famous for designing and marketing audio products that offer a demonstrably higher level of performance, but at real-world price points,' commented Jim Herd, President of Polk Audio. 'Our product line offers superior performance for consumers who demand a better home theater experience, making Polk Audio the perfect complement to Best Buy's tremendous selection of flat-panel TVs and other home entertainment products
O/T----- UFC 80-- All main card Fights.. Link attached:
http://mmafightvideos.blogspot.com/
NEW LINK- Watch UFC 80- All main card Fights...............
http://mmafightvideos.blogspot.com/
UFC 80- BJ Penn VS Joe Stevenson link
http://www.dailymotion.com/search/ufc+80/video/x43qzf_ufc-80-fight-bj-penn-fedor-crocop-s_sport
UFC tries to get these links taken down. Enjoy while you can
60- Did you get your 4.18's ?..........s
60- joined you at 4.32...........s
60- Any bounce in NCT today ??........s
Thanks Bull- Good Site................s
MC, I watched it. Just was not sure it was her. She nearly knocked that one girl out. Loved it...GLTY..........s
GM Cru, Was Gina- Crush on the show ??
Missed it. Can't wait to see her..............s
Choi: Standing at 2.18 m (7 ft 2 in) and weighing between 160 kg (352 lb) and 166.6 kg (367 lb), he is the largest combative sport competitor in the world, even bigger and heavier than the former WBA Heavyweight Champion Nicolay Valuev..
FEDOR vs CHOI Link attached:
http://mmafightvideos.blogspot.com/2007/12/fedor-emelianenko-vs-hong-man-choi.html
UFC 79 Hughes vs St Pierre........Link attached
http://mmafightvideos.blogspot.com/2007/12/ufc-79-streaming-video-georges-st.html
Some volume yesterday...........
Fake wall @ .24 imo...................s
nice call pinto.............
Where's the guy who was waiting for .71 cents this week ?? LOL
Great Trading Day...............
Any News Out ?? tia
GeoVax-GOVX-Dr.Harriet Robinson Named 2007 AAAS Fellow
ATLANTA, Nov. 7 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc. (OTC Bulletin Board: GOVX), an Atlanta based biotechnology company, announces that its Chief Scientific Advisor Harriet Robinson, Ph.D. has been elected 'Fellow of the American Association for the Advancement of Science (AAAS).' Election as a 'Fellow' is an honor bestowed upon AAAS members by their peers because of their contributions to advance science or its applications. Emory University professor and Asa Griggs scholar, Dr. Robinson co-founded GeoVax Labs, Inc. and is one of the world's leading HIV/AIDS vaccine scientists.
Recognized by the AAAS section on medical sciences, Dr. Robinson was elected for her outstanding work on retrovirus biology and the development of DNA vaccines with special emphasis on HIV/AIDS vaccines. In addition to her role as GeoVax's Chief Scientific Advisor, Dr. Robinson is chair of the Division of Microbiology and Immunology at Yerkes National Primate Research Center, a professor of microbiology and immunology in Emory University School of Medicine and an investigator in the Emory Vaccine Center.
GeoVax HIV/AIDS vaccine technologies were developed by Dr. Robinson in collaboration with colleagues at Emory University's Vaccine Center, the National Institutes of Health (NIH), and the Centers for Disease Control and Prevention (CDC). GeoVax HIV/AIDS vaccines are moving forward in human clinical trials administered by the HIV Vaccine Trials Network (HVTN). Four (4) Phase 1 human trials involving over 115 individuals are currently underway and Phase 2 trials are being planned for 2008.
Licensed by GeoVax, this innovative, two-step vaccine administration strategy utilizes DNA vaccines to prime the human immune system and recombinant MVA vaccines to boost the immune response against the AIDS virus. Both vaccines express greater than 50% of AIDS virus' (HIV-1) components and stimulate an antibody response as well as a T-cell response. Neither vaccine can cause AIDS. Early studies conducted at Emory University demonstrated successful long-term protection against the development of AIDS in non-human primates where 22 of 23 vaccinates were protected against AIDS development for nearly four years (trial concluded).
'Dr. Robinson is an outstanding scientist most deserving of this distinction,' said Don Hildebrand, President, CEO and Chairman of GeoVax Labs, Inc. 'As a co-founder of GeoVax, Dr. Robinson has been instrumental in the success our company has achieved to date. Her leadership in HIV/AIDS vaccine research is invaluable. I believe her contributions will positively impact the lives of millions of people worldwide.'
Dr. Robinson's recognition as AAAS Fellow was announced in the AAAS News & Notes section of the journal Science on 26 October 2007. She will be awarded an official certificate and pin on Saturday, February 16th at the Fellows Forum during the 2008 AAAS Annual Meeting in Boston.
About GeoVax Labs, Inc. (www.geovax.com)
GeoVax Labs, Inc. is a biotechnology company, established to develop, manufacture, license and commercialize human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents. GeoVax's vaccine technology is protected by 20 filed patent applications and issued patents.
GeoVax HIV/AIDS vaccines are designed to prevent development of Acquired Immunodeficiency Disease (AIDS), caused by the virus known as HIV-1, by vaccinating individuals prior to infection with the AIDS virus. In addition, GeoVax AIDS vaccines may be effective as therapeutics (treatment of people infected with AIDS virus). Studies evaluating these vaccines in already HIV/AIDS infected individuals are being planned.
GeoVax Co-Founder Dr. Harriet Robinson Named 2007 AAAS Fellow
ATLANTA, Nov. 7 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc. (OTC Bulletin Board: GOVX), an Atlanta based biotechnology company, announces that its Chief Scientific Advisor Harriet Robinson, Ph.D. has been elected 'Fellow of the American Association for the Advancement of Science (AAAS).' Election as a 'Fellow' is an honor bestowed upon AAAS members by their peers because of their contributions to advance science or its applications. Emory University professor and Asa Griggs scholar, Dr. Robinson co-founded GeoVax Labs, Inc. and is one of the world's leading HIV/AIDS vaccine scientists.
Recognized by the AAAS section on medical sciences, Dr. Robinson was elected for her outstanding work on retrovirus biology and the development of DNA vaccines with special emphasis on HIV/AIDS vaccines. In addition to her role as GeoVax's Chief Scientific Advisor, Dr. Robinson is chair of the Division of Microbiology and Immunology at Yerkes National Primate Research Center, a professor of microbiology and immunology in Emory University School of Medicine and an investigator in the Emory Vaccine Center.
GeoVax HIV/AIDS vaccine technologies were developed by Dr. Robinson in collaboration with colleagues at Emory University's Vaccine Center, the National Institutes of Health (NIH), and the Centers for Disease Control and Prevention (CDC). GeoVax HIV/AIDS vaccines are moving forward in human clinical trials administered by the HIV Vaccine Trials Network (HVTN). Four (4) Phase 1 human trials involving over 115 individuals are currently underway and Phase 2 trials are being planned for 2008.
Licensed by GeoVax, this innovative, two-step vaccine administration strategy utilizes DNA vaccines to prime the human immune system and recombinant MVA vaccines to boost the immune response against the AIDS virus. Both vaccines express greater than 50% of AIDS virus' (HIV-1) components and stimulate an antibody response as well as a T-cell response. Neither vaccine can cause AIDS. Early studies conducted at Emory University demonstrated successful long-term protection against the development of AIDS in non-human primates where 22 of 23 vaccinates were protected against AIDS development for nearly four years (trial concluded).
'Dr. Robinson is an outstanding scientist most deserving of this distinction,' said Don Hildebrand, President, CEO and Chairman of GeoVax Labs, Inc. 'As a co-founder of GeoVax, Dr. Robinson has been instrumental in the success our company has achieved to date. Her leadership in HIV/AIDS vaccine research is invaluable. I believe her contributions will positively impact the lives of millions of people worldwide.'
Dr. Robinson's recognition as AAAS Fellow was announced in the AAAS News & Notes section of the journal Science on 26 October 2007. She will be awarded an official certificate and pin on Saturday, February 16th at the Fellows Forum during the 2008 AAAS Annual Meeting in Boston.
About GeoVax Labs, Inc. (www.geovax.com)
GeoVax Labs, Inc. is a biotechnology company, established to develop, manufacture, license and commercialize human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents. GeoVax's vaccine technology is protected by 20 filed patent applications and issued patents.
GeoVax HIV/AIDS vaccines are designed to prevent development of Acquired Immunodeficiency Disease (AIDS), caused by the virus known as HIV-1, by vaccinating individuals prior to infection with the AIDS virus. In addition, GeoVax AIDS vaccines may be effective as therapeutics (treatment of people infected with AIDS virus). Studies evaluating these vaccines in already HIV/AIDS infected individuals are being planned.
TOA could go soon...............
GOVX- Excellent Results GeoVax HIV/AIDS Vaccine Trial
Friday November 2, 12:11 pm ET
ATLANTA, /PRNewswire-FirstCall/ -- GeoVax Labs, Inc. (OTC Bulletin Board: GOVX - News), an Atlanta based biotechnology company, announced today excellent safety and immunogenicity data from its full-dose HIV/AIDS vaccine human trial which began in September 2006.
ADVERTISEMENT
This full-dose trial is the second in a series of four Phase 1 human trials designed to test the safety and immunogenicity of the GeoVax HIV/AIDS vaccines. Involving 36 participants of which 30 received vaccine and 6 received placebo, this trial protocol included vaccination with two full-doses of GeoVax's DNA vaccine to prime the immune response followed by two full- doses of GeoVax's MVA vaccine to boost the immune response. GeoVax's DNA and MVA vaccines express over 50% of the AIDS virus (HIV-1) protein components in order to stimulate a broad anti-HIV immune response. The vaccines cannot cause AIDS because they do not include complete virus. A Phase 1 human trial, started in April 2006, evaluated the delivery of only 1/10th of the full dosage and utilized the same vaccine regimen evaluated in the full dose trial.
From data collected from the 26 participants who completed the trial, the following positive conclusions were observed:
-- GeoVax HIV/AIDS vaccines, both DNA and MVA, continue to demonstrate that they are quite safe and immunogenic following the delivery of the four full-doses (two of each vaccine) used in the trial's protocol
-- The full-dose regimen of GeoVax vaccines continues to be well tolerated without any type of reaction, mild or systemic, in the majority of participants
-- CD4 T-cell and CD8 T-cell responses are very evident both in the 1/10th dose and full-dose vaccine recipients
-- Antibody responses to the envelope glycoprotein (Env) increased following the fourth vaccination, and were present in 88% of the full-dose participants
-- Delivery of the fourth vaccination increased the frequency and magnitude of the CD8 T-cell and Antibody responses
Two additional Phase 1 human trials testing different vaccine regimens started in June 2007 and are currently in process. Planning of a large Phase 2 trial is underway and tentatively scheduled for a mid-2008 start.
"These results extend the earlier positive results for both our full and 1/10th dose groups to a larger number of volunteers," says Dr. Harriet Robinson, GeoVax Chief Scientific Advisor. "They are extremely encouraging and provide a strong foundation for proceeding with phase 2 human testing."
The human trials, testing GeoVax's HIV/AIDS vaccines, are conducted by the HIV Vaccine Trials Network (HVTN) based in Seattle, Washington. The HVTN, funded and supported by the National Institutes of Health (NIH), is the largest worldwide clinical trials program dedicated to the development and testing of HIV/AIDS vaccines. Preclinical work enabling the development of the clinical evaluation of GeoVax's DNA and MVA vaccines was funded by the National Institute of Allergy and Infectious Diseases of the US National Institute of Health. The NIH recently provided additional support to GeoVax's vaccine development program in the form of a $15 million IPCAVD grant awarded in October 2007.
About GeoVax Labs, Inc. (www.geovax.com)
Nice Rally ..............
OT- Pickle Attack ----------- Link Attached:
http://www.msnbc.msn.com/id/21547489/?GT1=10450